A serious adverse event puts ADVM-022’s future in doubt, and it could hurt other eye disease gene therapy players too.
Merck & Co gives up on MK-7110, and on molnupiravir in hospitalised patients.
The US pauses use of JNJ-78436735 after six cases of cerebral venous sinus thrombosis.
Picking up the Lilly cast-off might not have been an easy win for Provention after all.
Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.